19. November 2009 03:50
ImmuPharma PLC the specialist discovery and development pharmaceutical company is pleased to announce today the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care.
[More]
18. November 2009 01:04
Representatives of the nation's leading public and private research universities, joined by Speaker Nancy Pelosi and other Members of Congress, today announced the launch of ScienceWorksForUS, an initiative that will highlight the scientific research and related activities that have been made possible by the American Recovery and Reinvestment Act of 2009 (ARRA), also known as the stimulus.
[More]
17. November 2009 03:22
Galapagos NV announced today that it has started a Phase II clinical study to evaluate Nanocort's effectiveness in treating flares in multiple sclerosis (MS). Nanocort combines less frequent treatment with lower dosage and potentially more effective delivery than other MS flare treatments.
[More]
c671443c-7394-49e8-a18e-5988be78afd0|0|.0
Posted in: Drug Trial News
Tags: Antibody, Arthritis, Autoimmune Disease, Bone, Brain, Corticosteroid, Liposome, Metastasis, Multiple Sclerosis, Myelin, Nervous System, Rheumatoid Arthritis, Steroid
16. November 2009 10:40
Seattle Genetics, Inc. today announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company’s proprietary technology.
[More]
c39fca64-5a76-4779-9918-3fae4e22b2af|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Antibody, Autoimmune Disease, Biotechnology, Brentuximab Vedotin, Cancer, Cell, Genetics, Glioblastoma, Kidney Cancer, Lymphoma, Monoclonal Antibody, Multiple Myeloma, Oncology, Renal Cell Carcinoma
16. November 2009 02:07
In the largest, most comprehensive genetic analysis of childhood-onset inflammatory bowel disease (IBD), an international research team has identified five new gene regions, including one involved in a biological pathway that helps drive the painful inflammation of the digestive tract that characterizes the disease.
[More]
13. November 2009 01:18
Lexicon Pharmaceuticals, Inc. announced today that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS).
[More]
b8bfc27c-e4f7-4931-bfab-38e1c3d4316b|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Abdominal Pain, Arthritis, Autoimmune Disease, Biomarker, Constipation, Diabetes, Diarrhea, Glaucoma, Irritable Bowel Syndrome, Rheumatoid Arthritis, Serotonin, Tryptophan, Type 2 Diabetes
12. November 2009 08:51
arGentis Pharmaceuticals, LLC today announced that it will collaborate with the University of Tennessee Health Science Center (UTHSC) and the Veterans Affairs Medical Center of Memphis (VAMC) to initiate the first human clinical evaluation of an oral altered peptide ligand (APL), ARG301, in a Phase I study of Rheumatoid Arthritis patients.
[More]
7. November 2009 00:33
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
[More]
2. November 2009 08:54
SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's automated SQiDworks(TM) Diagnostics Platform and its multiplexed IgXPLEX(TM) rheumatoid arthritis (RA) assay for marketing in the United States.
[More]
2. November 2009 08:04
Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181. Avila showed that AVL-181 promoted complete viral clearance in vitro when used at clinically-relevant concentrations in combination with other HCV therapies.
[More]
2. November 2009 04:07
The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - the second positive phase 3 clinical trial of Benlysta (belimumab), the first successfully tested new drug developed specifically for people with systemic lupus.
[More]
2. November 2009 03:32
Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) today announced positive results from BLISS-76, the second of two large-scale phase III clinical trials of BENLYSTA(TM) (belimumab) for treating systemic lupus. A full presentation of results from BLISS-52 was recently shared at the 73rd Annual Scientific meeting of the American College of Rheumatology. Both trials succeeded in meeting their primary endpoints, which should make BENLYSTA eligible for approval by the U.S. Food and Drug Administration (FDA).
[More]
2. November 2009 03:32
Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care.
[More]
42070d4c-8702-4623-8c76-574bdadc197c|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Anthrax, Antibody, Arthritis, Autoimmune Disease, Cancer, Coronary Heart Disease, Diabetes, Hepatitis C, Lupus, Monoclonal Antibody, Nervous System, Pharmacology, Steroid, Systemic Lupus Erythematosus
2. November 2009 01:18
Individuals with a history of lupus who receive a kidney transplant rarely develop the serious inflammatory condition lupus nephritis in their new organ, according to a paper being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.
[More]
30. October 2009 07:00
At its most benign, the autoimmune disease scleroderma can discolor parts of the skin of its sufferers. At its most pernicious, it can thicken and harden their skin, their blood vessels, and their internal organs before, in many cases, killing them.
[More] 
Subscribe